- Coordinates
 - PDB Format
 - Method
 - ELECTRON MICROSCOPY
 - Oligo State
 - hetero-3-1-1-mer
 - Ligands
 - 12 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
 - 30 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
 NAG.13: 1 residues within 4Å:- Chain A: N.48
 
Ligand excluded by PLIPNAG.14: 6 residues within 4Å:- Chain A: N.107, T.109, N.110, V.111, V.112, F.139
 
Ligand excluded by PLIPNAG.15: 2 residues within 4Å:- Chain A: N.146, N.147
 
Ligand excluded by PLIPNAG.16: 6 residues within 4Å:- Chain A: N.218, T.220
 - Chain B: R.441, S.443, N.444, K.446
 
Ligand excluded by PLIPNAG.17: 2 residues within 4Å:- Chain A: N.266
 - Chain B: K.542
 
Ligand excluded by PLIPNAG.18: 5 residues within 4Å:- Chain A: R.312, F.313, N.315, T.317, Q.564
 
Ligand excluded by PLIPNAG.19: 2 residues within 4Å:- Chain A: D.323, N.327
 
Ligand excluded by PLIPNAG.20: 4 residues within 4Å:- Chain A: N.600, T.602, E.603, Q.628
 
Ligand excluded by PLIPNAG.21: 2 residues within 4Å:- Chain A: N.689
 - Chain E: G.778
 
Ligand excluded by PLIPNAG.22: 3 residues within 4Å:- Chain A: A.686, E.1052, N.1054
 
Ligand excluded by PLIPNAG.23: 2 residues within 4Å:- Chain B: Y.15, N.48
 
Ligand excluded by PLIPNAG.24: 3 residues within 4Å:- Chain B: N.107, T.109, V.112
 
Ligand excluded by PLIPNAG.25: 3 residues within 4Å:- Chain B: E.117, N.146, N.147
 
Ligand excluded by PLIPNAG.26: 2 residues within 4Å:- Chain B: N.218, T.220
 
Ligand excluded by PLIPNAG.27: 2 residues within 4Å:- Chain B: N.266
 - Chain E: K.542
 
Ligand excluded by PLIPNAG.28: 1 residues within 4Å:- Chain B: N.315
 
Ligand excluded by PLIPNAG.29: 2 residues within 4Å:- Chain B: D.323, N.327
 
Ligand excluded by PLIPNAG.30: 3 residues within 4Å:- Chain B: N.600, E.603, Q.628
 
Ligand excluded by PLIPNAG.31: 2 residues within 4Å:- Chain B: N.689, N.690
 
Ligand excluded by PLIPNAG.32: 3 residues within 4Å:- Chain B: A.686, E.1052, N.1054
 
Ligand excluded by PLIPNAG.33: 2 residues within 4Å:- Chain E: Y.15, N.48
 
Ligand excluded by PLIPNAG.34: 3 residues within 4Å:- Chain E: N.107, T.109, V.112
 
Ligand excluded by PLIPNAG.35: 2 residues within 4Å:- Chain E: E.117, N.147
 
Ligand excluded by PLIPNAG.36: 1 residues within 4Å:- Chain E: N.218
 
Ligand excluded by PLIPNAG.37: 2 residues within 4Å:- Chain A: K.542
 - Chain E: N.266
 
Ligand excluded by PLIPNAG.38: 4 residues within 4Å:- Chain E: N.315, I.316, T.317, V.346
 
Ligand excluded by PLIPNAG.39: 2 residues within 4Å:- Chain E: D.323, N.327
 
Ligand excluded by PLIPNAG.40: 4 residues within 4Å:- Chain E: N.600, T.602, E.603, Q.628
 
Ligand excluded by PLIPNAG.41: 2 residues within 4Å:- Chain B: Y.776
 - Chain E: N.689
 
Ligand excluded by PLIPNAG.42: 2 residues within 4Å:- Chain E: A.686, N.1054
 
Ligand excluded by PLIP- Links
 - RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
 - Citation
 - Yu, H. et al., Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants. Nat Commun (2023)
          


 - Release Date
 - 2023-01-25
 - Peptides
 - Spike glycoprotein: ABE
Light chain of YB9-258 Fab: C
Heavy chain of YB9-258 Fab: D - SMTL:PDB
 - SMTL Chain Id:
PDB Chain Id:A
BB
CE
AC
LD
H 
- Coordinates
 - PDB Format
 - Method
 - ELECTRON MICROSCOPY
 - Oligo State
 - hetero-3-1-1-mer
 - Ligands
 - 12 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
 - 30 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
 - Links
 - RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
 - Citation
 - Yu, H. et al., Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants. Nat Commun (2023)
          


 - Release Date
 - 2023-01-25
 - Peptides
 - Spike glycoprotein: ABE
Light chain of YB9-258 Fab: C
Heavy chain of YB9-258 Fab: D - SMTL:PDB
 - SMTL Chain Id:
PDB Chain Id:A
BB
CE
AC
LD
H